At the archive date, IQVIA HOLDINGS INC. was expected to release its Q3 2026 10-Q filing on October 26, 2026, before market open. Last quarter: IQVIA's revenue grew 8.7% year-over-year to $4,368 million in Q2 2026, driven by growth in both the Commercial Solutions and Research & Development Solutions segments, though segment profit growth was offset by higher restructuring costs and general corporate expenses, keeping consolidated segment profit flat at $506 million.
EPS Estimate
$3.31
Revenue Estimate
$4.4B
Analyst consensus captured from Finnhub and Financial Modeling Prep. This archived preview is no longer updated with later results; see the IQV page for retained reports.
Drawn from management commentary in the Q2 2026 10-Q:
Q2 2026 revenues increased $351 million (8.7%) year-over-year to $4,368 million, comprised of constant currency growth of ~$343 million (8.5%), with Commercial Solutions up $139 million and Research & Development Solutions up $204 million. For the six months ended June 30, 2026, revenues rose 8.6% to $8,519 million.
IQVIA moved from three segments to two: Contract Sales & Medical Solutions was folded into the renamed Commercial Solutions segment, and certain Real-World offerings moved into Research & Development Solutions, reflecting an updated operating model aligned with how the CODM reviews performance.
Research & Development Solutions contracted backlog increased from $34.0 billion (recast) as of December 31, 2025 to $34.2 billion as of June 30, 2026, with approximately $9.2 billion expected to convert to revenue over the next twelve months.
Revenue
$4.37B
+8.74% YoY
EPS (Diluted)
$1.53
-0.65% YoY
Operating Income
$506M
0.00% YoY
Add IQV to your watchlist to keep its archived reports easy to find. New filing alerts are no longer sent.